Home > Oncology > ESMO 2021 > Genitourinary Cancer > PARP inhibitor rechallenge improves PFS in ovarian cancer

PARP inhibitor rechallenge improves PFS in ovarian cancer

Presented By
Dr Eric Pujade-Lauraine, Université Paris Descartes, France
Conference
ESMO 2021
Trial
Phase 3, OReO/ENGOT Ov-38
Results from the phase 3 OReO/ENGOT Ov-38 trial demonstrated that rechallenge with maintenance olaparib significantly prolonged progression-free survival (PFS) compared with placebo in both BRCA1/2-mutated and non-BRCA1/2-mutated disease. Although most patients achieve a long-term response, most ultimately progress on PARP inhibitor maintenance therapy. The randomised, double-blind, phase 3 OReO/ENGOT Ov-38 study (NCT03106987) evaluated PARP inhibitor maintenance re-treatment in this setting. Dr Eric Pujade-Lauraine (Université Paris Descartes, France) presented the results [1]. A total of 112 patients were BRCA1/2 mutated (BRCAm) and 108 patients were non-BRCA mutated (non-BRCAm). Patients were heavily pre-treated, with 93% (BRCAm) and 86% (non-BRCAm) receiving ≥3 prior lines of any chemotherapy...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on